Dren Bio Inc. has entered into a strategic collaboration with Novartis Pharma AG which will focus on the discovery and development of therapeutic bispecific antibodies for cancer leveraging Dren Bio’s proprietary Targeted Myeloid Engager and Phagocytosis Platform.
The targeted delivery of radionucleotides into tumors, known as radioimmunotherapy (RIT), has proven effective mainly in hematological cancer treatment, but its usefulness in solid tumors needs further exploration. Researchers from Oncoone Research & Development GmbH described the use of Pretarg-it, a novel pre-targeted RIT strategy that consists of ON-105 and the radioactively labeled DOTA-di-HSG peptide.
Scientists at the University of Washington have engineered human plasma B cells modified to express long-lasting bispecific antibodies that could be used to treat leukemia without requiring continuous dosing.
Beijing Gensciences Inc. has developed a FVIIIa-mimetic bispecific antibody named SS-315 for the treatment of hemophilia A. SS-315 was developed by targeting FX with its upper Fab arms and FIXa with its down-side scFv arms, respectively; the hemostatic potential of SS-315 was investigated in vitro and in vivo.
Scientists at the University of Washington have engineered human plasma B cells modified to express long-lasting bispecific antibodies that could be used to treat leukemia without requiring continuous dosing.
“We are trying to engineer plasma cells to make as a stable source for biologic drugs. One thing that is really unique about plasma cells is that they can live for a really long time … up to 10 years or even 100 years depending on the type of plasma cell that that you make,” Richard James, senior author of the study, principal investigator at Seattle Children’s Research Institute, and associate professor at the University of Washington, told BioWorld.
CDR-Life Inc. has expanded its pipeline of novel T-cell engagers (TCE) with the addition of CDR-813 and CDR-505. CDR-813 is a highly potent and selective TCE candidate targeting tumors expressing PRAME (preferentially expressed antigen in melanoma) in HLA-A*02:01 patients.
South Korea’s Imbiologics Inc. scored a potential $940 million (₩1.3 trillion) technology transfer deal with U.S. biotech Navigator Medicines Inc. for its bispecific antibody drug candidate, IMB-101 (Oxtima), to treat autoimmune diseases.
Zymeworks Inc. has obtained IND clearance from the FDA for ZW-171, a novel T-cell targeting bispecific antibody for mesothelin (MSLN)-expressing cancers. Clinical development will begin this year, and additional applications will be filed in the second half of the year seeking trial clearances in other territories.
Indupro Inc. has announced a $85 million series A financing to support its work on precisely defining the spatial proximity of proteins on the surface of cells with high therapeutic potential across a broad range of indications and applications, including for the treatment of cancer and autoimmune diseases.
Two years after signing a $1.6 billion partnership with Marengo Therapeutics Inc., Paris-based Ipsen SA is back at it again, this time teaming up for two additional assets that target “cold” tumors in a deal that could bring privately held Marengo $1.2 billion. “We do something really novel and innovative and I think it’s very important to continue to validate it,” Marengo CEO Zhen Su told BioWorld, adding that with the newest deal, “we see validation all around this … It’s a success on success.”
RSS
